Investigating the effect of echinacea extraction syrup on the outcomes of lower respiratory infections in patients with COVID-19: a randomized clinical trial study.

Investigating the effect of echinacea extraction syrup on the outcomes of lower respiratory infections in patients with COVID-19: a randomized clinical trial study.

Publication date: Dec 19, 2024

Many COVID-19 patients experience mild to severe symptoms, including respiratory system involvement. Different treatment instructions have been suggested for patients with COVID-19. Echinacea has known antiviral effects. However, there is still not enough evidence that it is effective in treating COVID-19. This study was conducted with the aim of determining the effect of Echinacea extract syrup on the outcomes of the lower respiratory tract in patients with COVID-19. In this single-blind randomized controlled trial, 40 patients with COVID-19 who were inpatients in the hospitals of Mashhad University of Medical Sciences, Iran, were randomly selected and assigned to two equal control and experimental groups (nā€‰=ā€‰20). In addition to receiving routine care and treatment (oxygen supply, remdesivir, enoxaparin and heparin), the experimental group received 5 cubic centimeter (CC) of Imogen syrup three times a day for 5 days each. The control group only received routine care and treatment. The data were collected on the first, third and fifth days after hospitalization and were analyzed using descriptive and analytical tests in Statistical Package for the Social Sciences (SPSS). The significance level was set at pā€‰ā€‰0. 05). The consumption of Echinacea extract syrup may not be able to improve the symptoms of acute lower respiratory tract infection in patients with COVID-19 with 3 daily doses for 5 days. More studies should be conducted to investigate the clinical effects of Echinacea extract in the treatment of patients with pulmonary complications. IRCT20130522013423N2.

Open Access PDF

Concepts Keywords
Daily Adult
Inpatients Aged
Iran Antiviral Agents
Irct20130522013423n2 Antiviral Agents
Randomized COVID-19
COVID-19
COVID-19 Drug Treatment
Echinacea
Echinacea
Female
Humans
Iran
Male
Middle Aged
Plant Extracts
Plant Extracts
RCT
Respiratory Tract Infections
SARS-CoV-2
Single-Blind Method
Treatment Outcome

Semantics

Type Source Name
drug DRUGBANK Echinacea
disease MESH respiratory infections
disease MESH COVID-19
drug DRUGBANK Aspartame
drug DRUGBANK Oxygen
drug DRUGBANK Enoxaparin
drug DRUGBANK Heparin
disease MESH complications
pathway REACTOME Reproduction
drug DRUGBANK Coenzyme M
disease IDO blood
disease IDO intervention
disease MESH pneumonia
disease MESH infections
disease IDO protein
drug DRUGBANK Serine
disease IDO host
disease IDO infection
disease MESH respiratory diseases
disease MESH central nervous system diseases
drug DRUGBANK Lopinavir
disease IDO immunodeficiency
drug DRUGBANK Chloroquine
drug DRUGBANK Nonoxynol-9
disease MESH influenza
pathway REACTOME Immune System
disease MESH urinary tract infections
drug DRUGBANK Tretamine
disease MESH contraindication
disease MESH nervous system autoimmune diseases
disease MESH deformity
disease MESH sore throat
drug DRUGBANK Ademetionine
disease IDO history
drug DRUGBANK Ranitidine
disease MESH purpura
drug DRUGBANK Xanthan gum
drug DRUGBANK Citric Acid
drug DRUGBANK Sorbitol
drug DRUGBANK Water
drug DRUGBANK Trestolone
drug DRUGBANK Hydrocortisone
disease IDO symptom
disease IDO production
drug DRUGBANK Isoxaflutole
disease MESH common cold
disease MESH leukemia
drug DRUGBANK Echinacea angustifolia root
disease MESH hypoxia
pathway REACTOME Innate Immune System
drug DRUGBANK Oseltamivir
disease MESH viral shedding
disease MESH chronic diseases
drug DRUGBANK Favipiravir
disease MESH liver diseases
drug DRUGBANK Echinacea purpurea
disease MESH acute lymphoblastic leukemia
disease MESH tic

Original Article

(Visited 1 times, 1 visits today)